EUVIMEDEUVIMED entdecken
Crossref

Lessons learned: real-world effectiveness of dupilumab in patients with eosinophilic esophagitis

Carl Olson, Jameel Alp, Nicha Wongjarupong, Joshua A Sloan iD

Diseases of the Esophagus · 2025

DOI: 10.1093/dote/doaf123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diseases of the Esophagus, 2025. Verfasst von Carl Olson und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Minnesota School of Medicine, Minneapolis, MN, USA. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus. Dupilumab, an IL-4/IL-13 inhibitor, was approved for EoE in 2022, but real-world data remain limited. We evaluated its effectiveness in a single tertiary care center uninvolved in prior clinical trials. We conducted a retrospective cohort study of adults (≥18 years) with confirmed EoE (≥15 eos/hpf) who initiated dupilumab therapy between 1/2022 and 10/2024 and evaluated symptom burden, endoscopic severity, histologic activity, as well as adverse events. Ultimately, 44 patients were included with significant decreases in clinical symptom and endoscopic scoring. Peak eosinophil counts declined by a median of 47.5 eos/hpf. Histologic remission occurred in 76.9% at follow-up 1 and maintained in 72.7% at follow-up 2. About 15.9% of patients reported AEs and 9.1% discontinued therapy. These findings are consistent with the clinical trial and recent observational data, supporting dupilumab’s effectiveness and generalizability in real-world practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eosinophilic EsophagitisAntibodies, Monoclonal, HumanizedHumansMaleFemaleRetrospective StudiesAdultMiddle AgedTreatment OutcomeEosinophilsAgedSeverity of Illness Index

Stichwörter der Autor:innen

biologic therapydupilumabeosinophilic esophagitis

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • University of Minnesota School of Medicine, Minneapolis, MN, USA.
  • Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
  • Division of Gastroenterology, Bangkok Hospital Pattaya, Chonburi, Thailand.
  • Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN, USA.

ORCID-Profile: Joshua A Sloan

Zitieren

APA

Olson, C., Alp, J., Wongjarupong, N., & Sloan, J. A. (2025). Lessons learned: real-world effectiveness of dupilumab in patients with eosinophilic esophagitis. Diseases of the Esophagus. https://doi.org/10.1093/dote/doaf123

Vancouver

Olson C, Alp J, Wongjarupong N, Sloan JA. Lessons learned: real-world effectiveness of dupilumab in patients with eosinophilic esophagitis. Diseases of the Esophagus. 2025. doi:10.1093/dote/doaf123

BibTeX
@article{Olson2025,
  author = {Olson, Carl and Alp, Jameel and Wongjarupong, Nicha and Sloan, Joshua A},
  title = {Lessons learned: real-world effectiveness of dupilumab in patients with eosinophilic esophagitis},
  journal = {Diseases of the Esophagus},
  year = {2025},
  doi = {10.1093/dote/doaf123}
}
Kostenlos starten →